Indivior Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Indivior Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Indivior Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Indivior Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Indivior Pharmaceuticals Inc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectables for the treatment of opioid dependence, and buprenorphine-based injectable suspension for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses products for substance use disorder and cannabis disorder. Indivior offers products in various formulations, including tablets, nasal sprays, transmucosal films, and injectables. The company offers its products across various countries globally. Indivior is headquartered in North Chesterfield, Virginia, the US.
Headquarters
United States of America
Address
Suite 125, 10710 Midlothian Turnpike, Chesterfield, Virginia, 23235
Website
www.indivior.com
Telephone
1 804 3791090
No of Employees
827
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INDV (NASD)
Revenue (2024)
$1.2B
4.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
2900%
(2024 vs 2023)
Market Cap*
$5.0B
Net Profit Margin (2024)
XYZ
2,772.9%
(2024 vs 2023)
* As of and is in US$
Indivior Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Opioid Dependence Drugs: | Suboxone |
| Suboxone (Sublingual Film/Sublingual Tablet) | Subutex |
| Subutex (Sublingual Tablet) | Sublocade |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In February, the company received label changes approval from the US Food and Drug Administration for SUBLOCADE including a rapid initiation protocol and alternative injection sites, advancement in the treatment of moderate to severe opioid use disorder. |
| 2024 | Regulatory Approval | In October, the company received a grant for Priority Review designation from the U.S. Food and Drug Administration for SUBLOCADE (buprenorphine extended-release) injection. |
| 2024 | Contracts/Agreements | In August, the company secured its order for OPVEE (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority. |
Competitor Comparison
| Key Parameters | Indivior Pharmaceuticals Inc | AstraZeneca Plc | Alkermes Plc | Filana Therapeutics Inc | GW Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | Ireland | United States of America | United Kingdom |
| City | Chesterfield | Cambridge | Dublin | Austin | Cambridge |
| State/Province | Virginia | Cambridgeshire | Dublin | Texas | England |
| No. of Employees | 827 | 96,100 | 2,050 | 17 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Wheadon | Chairman | Executive Board | 2025 | 67 |
| Joe Ciaffoni | Director; Chief Executive Officer | Executive Board | 2025 | - |
| Ryan Preblick | Chief Financial Officer | Senior Management | 2020 | 49 |
| Vishal Kalia | Chief Strategy Officer; Chief Operating Officer | Senior Management | 2024 | 44 |
| Jeffrey Burris | Chief Legal Officer | Senior Management | 2021 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer